Sarafan ChEM-H
Showing 11-12 of 12 Results
-
Adrian Hugenmatter
Director of Protein Engineering
BioDr. Adrian Hugenmatter joined ChEM-H in 2021 and is leading the Protein Therapeutics Knowledge Center. Dr. Hugenmatter obtained his PhD in the laboratory of Prof. Donald Hilvert at the Swiss Federal Institute of Zurich (ETH Zurich), where he gained his first experience in enzymology, antibody engineering and directed evolution. Fascinated by protein engineering, he joined the laboratory of Prof. Dan Tawfik at the Weizmann Institute of Science (Israel), where he worked on molecular evolution. Dr. Hugenmatter then spent 11 years as a research scientist and team leader at Roche. During that time he developed and optimized several antibody lead candidates for therapeutic application in Oncology and Neuroscience. All along his career, Dr. Hugenmatter was and still is intrigued by the question how a ideal drug must look like to give the maximal benefit to the patient.
-
Paul S Humphries
Alliance Director, Sarafan ChEM-H
Current Role at StanfordAlliance Director, Stanford Innovative Medicines Accelerator (IMA)